Impact of GLP-1 and GLP-1 Receptor Agonists on Cardiovascular Risk Factors in Type 2 Diabetes

E-ISSN： 1875-6417|6|4|191-200

ISSN： 1573-3998

Source： Current Diabetes Reviews, Vol.6, Iss.4, 2010-07, pp. : 191-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1 receptor agonists in the treatment of Type 2 diabetes

By Ahrén Bo

Diabetes Management, Vol. 3, Iss. 5, 2013-09 ,pp. : 401-413

Future Medicine

Access to resources Recommend Favorite

Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus? (A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial)

Current Vascular Pharmacology, Vol. 14, Iss. 5, 2016-09 ,pp. : 469-473

Bentham Science Publishers

Access to resources Recommend Favorite

Albiglutide: clinical overview of a long-acting GLP-1 receptor agonist in the treatment of Type 2 diabetes

By Setji Tracy Feinglos Mark

Expert Review of Endocrinology and Metabolism, Vol. 8, Iss. 3, 2013-05 ,pp. : 229-238

Informa Healthcare

Access to resources Recommend Favorite

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Current Diabetes Reviews, Vol. 3, Iss. 1, 2007-01 ,pp. : 15-23

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Type 1 Diabetic Patients with Glucagon-Like Peptide-1 (GLP-1) and GLP-1R Agonists

Current Diabetes Reviews, Vol. 5, Iss. 4, 2009-11 ,pp. : 266-275

Bentham Science Publishers

Access to resources Recommend Favorite